ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0785

Identification of Recruited CCR2+ Inflammatory Monocytes in a Mouse Model of RA-associated Lung Disease with Potential Role for resolvin-D1 in Reducing Monocyte Inflammatory Responses

Austin Barry1, Geoffrey Thiele1, Ted Mikuls1, Michael Duryee1, Amy Nelson1, Rohit Gaurav1, Bryant England1 and Jill Poole1, 1University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2020

Keywords: autoantigens, diet, Monocytes/macrophages, pulmonary, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: RA – Etiology & Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk for comorbid chronic lung disease, with premature mortality. Therapies for RA-associated lung disease are limited. Organic dust extract (ODE)-induced airway inflammation model was previously combined with the collagen-induced arthritis (CIA) model to model RA-related lung disease. The combination of CIA+ODE resulted in increased arthritis severity and higher levels of anti-malondialdehyde-acetaldehyde (MAA) and anti-cyclic citrullinated (CIT) protein antibodies (vs. CIA or ODE alone). Co-exposure also promoted pro-fibrotic lung inflammatory features. CCR2+ monocytes migrate to lung tissues under inflammatory conditions to influence inflammatory fibrotic consequences and may be a target for therapies. We aimed to determine whether CCR2+ monocytes were recruited to the lungs in this mouse RA-lung disease model, and whether anti-inflammatory omega-3 fatty acid derivatives (DHA, resolvin-D1, and maresin-1) would reduce inflammatory responses in vitro from monocyte stimulation with ODE and/or autoreactive antigens.

Methods: Arthritis prone DBA/1J mice were assigned to 1 of 4 groups: Sham (saline injection/saline inhalation), CIA (CIA injection/saline inhalation), ODE (ODE inhalation/saline injection), or CIA+ODE treatment for 5 weeks as previously established. CCR2 expression was quantified using confocal microscopy in murine lung sections. In cell culture studies, human THP-1 monocytes were exposed to varying doses of: ODE, CIT peptides, and MAA-adducted protein, and the combination of ODE + autoantigens. In parallel experiments, cells were pre-treated for one hour with docosahexaenoic acid (DHA) or its metabolites (maresin-1 and resolvin-D1) before stimulation. TNF-α was quantitated in cell-free culture supernatant by ELISA.

Results: In animal studies, CCR2 expression was significantly increased in lung tissues of treated animals CIA+ODE >CIA >ODE vs. sham (Figure 1; N=5 mice/group). In monocyte studies, TNF-α levels were significantly increased following stimulation with ODE (mean ± SEM pg/ml; 1104.2 ± 91.7), MAA (167.8 ± 19.3), and CIT (75.7 ± 22.4) as compared to control (7.4 ± 4.0) (N=9; p< 0.05). No additive effects were demonstrated when agents were combined. Pretreatment with resolvin-D1 significantly reduced ODE-induced TNF-α at 4 hours (75% reduction) and reduced MAA (58%) and CIT (55%) stimulated TNF-α release at only  48 hours. Pretreatment with DHA or maresin-1 did not reduce ODE or autoantigen stimulated TNF-α release. No cytotoxicity was detected with respective treatments.

Conclusion: Arthritis induction promotes the recruitment of CCR2+ monocytes to the lung and this response is augmented by airborne biohazard exposures to suggest that targeting recruited inflammatory monocytes may be a potential strategy. Reduction in TNF-α levels with resolvin-D1 pretreatment in monocytes strengthens the need of future in vivo studies to define whether specific dietary interventions focused on the omega-3 fatty acid resolvin-D1 might help in the prevention and/or treatment of RA-related lung disease.

Figure 1. CCR2+ monocytes are increased with ODE and CIA treatment conditions in murine lungs. Representative image (1 of 5) of CCR2 expression (yellow) of lung tissue from each treatment group. Bar graph depicts mean with standard error bars of CCR2 staining (N=5). Statistical difference ***p < 0.001 vs. saline/sham control and ###p < 0.001 denoted by line between groups.


Disclosure: A. Barry, None; G. Thiele, None; T. Mikuls, Horizon Therapeutics, 2; M. Duryee, None; A. Nelson, None; R. Gaurav, None; B. England, None; J. Poole, None.

To cite this abstract in AMA style:

Barry A, Thiele G, Mikuls T, Duryee M, Nelson A, Gaurav R, England B, Poole J. Identification of Recruited CCR2+ Inflammatory Monocytes in a Mouse Model of RA-associated Lung Disease with Potential Role for resolvin-D1 in Reducing Monocyte Inflammatory Responses [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/identification-of-recruited-ccr2-inflammatory-monocytes-in-a-mouse-model-of-ra-associated-lung-disease-with-potential-role-for-resolvin-d1-in-reducing-monocyte-inflammatory-responses/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-recruited-ccr2-inflammatory-monocytes-in-a-mouse-model-of-ra-associated-lung-disease-with-potential-role-for-resolvin-d1-in-reducing-monocyte-inflammatory-responses/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology